Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Disruption of sleep and alertness is one of the most disabling non-motor symptoms of Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not well understood, and treatment options remain limited. The proposed research will examine markers of the circadian system, sleepiness and sleep quality in PD patients and healthy controls. Further, the project will examine effects of bright light exposure on circadin function, sleep and alertness in PD.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
55 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank Criteria;
PD Hoehn and Yahr stage 2-4;
Pittsburgh Sleep Quality Index (PSQI) score >5 in group 1, and ≤5 in group 2;
Epworth Sleepiness Scale (ESS) score ≥10 in group 1, and <10 in group 2;
Control participants will be matched for gender and age with PD participants.
Atypical or secondary forms of Parkinsonism;
Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score of ≤ 26;
Presence of depression defined as the Beck Depression Inventory (BDI) score >14;
Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible at least 4 weeks after the taper is completed;
Use of SSRIs / SNRIs antidepressants, unless the participant has been on a stable dose for at least 3 months prior to the screening;
Use of medications known to affect melatonin secretion;